DrugPatentWatch Database Preview
Drugs in Development Information for MN-166
» See Plans and Pricing
What is the development status for investigational drug MN-166?
MN-166 is an investigational drug.
There have been 11 clinical trials for MN-166.
The most recent clinical trial was a Phase 1 trial, which was initiated on October 1st 2019.
The most common disease conditions in clinical trials are Sclerosis, Motor Neuron Disease, and Amyotrophic Lateral Sclerosis. The leading clinical trial sponsors are MediciNova, University of California, Los Angeles, and National Institute on Alcohol Abuse and Alcoholism (NIAAA).
There are seven hundred and seventeen US patents protecting this investigational drug and seven international patents.
Summary for MN-166
| US Patents | 717 |
| International Patents | 7,265 |
| US Patent Applications | 1,617 |
| WIPO Patent Applications | 889 |
| Japanese Patent Applications | 12 |
| Clinical Trial Progress | Phase 1 (2019-10-01) |
| Vendors | 83 |
Recent Clinical Trials for MN-166
| Title | Sponsor | Phase |
|---|---|---|
| Efficacy, Safety, Tolerability, and Biomarkers of MN-166 (Ibudilast) in Patients Hospitalized With COVID-19 and at Risk for ARDS | MediciNova | Phase 2 |
| Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS | MediciNova | Phase 2/Phase 3 |
| Relative Bioavailability of MN-166 (Ibudilast) in Extended Release Tablet vs. Intermediate-release Capsule in Healthy Volunteers | MediciNova | Phase 1 |
Clinical Trial Summary for MN-166
Top disease conditions for MN-166
Top clinical trial sponsors for MN-166
US Patents for MN-166
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| MN-166 | Start Trial | Heterocyclic compound | Takeda Pharmaceutical Company Limited (Osaka, JP) | Start Trial |
| MN-166 | Start Trial | Therapeutic approaches for treating Parkinson's disease | Pharnext (Issy les Moulineaux, FR) | Start Trial |
| MN-166 | Start Trial | Tolerogenic synthetic nanocarriers for generating CD8+ regulatory T cells | Selecta Biosciences, Inc. (Watertown, MA) | Start Trial |
| MN-166 | Start Trial | Method of purifying authentic trimeric HIV-1 GP140 envelope glycoproteins comprising a long linker and tag | The Catholic University of America (Washington, DC) | Start Trial |
| MN-166 | Start Trial | Ultra-pure agonists of guanylate cyclase C, method of making and using same | SYNERGY PHARMACEUTICALS, INC. (New York, NY) | Start Trial |
| MN-166 | Start Trial | Melanocortin-1 receptor-specific cyclic hexapeptides | Palatin Technologies, Inc. (Cranbury, NJ) | Start Trial |
| MN-166 | Start Trial | Pyrazolopyridines and pyrazolopyrimidines | Pfizer Inc. (New York, NY) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for MN-166
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| MN-166 | Canada | 2961033 | 2034-09-11 | Start Trial |
| MN-166 | European Patent Office | 3192791 | 2034-09-11 | Start Trial |
| MN-166 | Japan | WO2016039408 | 2034-09-11 | Start Trial |
| MN-166 | World Intellectual Property Organization (WIPO) | 2016039408 | 2034-09-11 | Start Trial |
| MN-166 | Australia | 2012222348 | 2031-03-01 | Start Trial |
| MN-166 | Australia | 2012222351 | 2031-03-01 | Start Trial |
| MN-166 | Australia | 2013224959 | 2031-03-01 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
